Loading
ADRIATIC brought the first improvement in curative-intent small-cell lung cancer treatment in 30 years: a year or two of immunotherapy after chemoradiation lengthens life.
ADRIATIC, trial NCT03703297 sponsored by AstraZeneca and reported in 2024, brought the first improvement in curative-intent small-cell lung cancer treatment in thirty years: durvalumab consolidation for up to two years after concurrent chemoradiotherapy for limited-stage disease lengthens life. It randomised 730 patients without progression after chemoradiation to durvalumab or placebo and met both primary endpoints of overall and progression-free survival, leading to FDA approval on 4 December 2024, with benefit regardless of prophylactic cranial irradiation. OnCo links it to small-cell lung cancer, modern radiotherapy, prophylactic cranial irradiation, durvalumab, the limited-stage and PCI terms and Corinne Faivre-Finn, and it applies the PACIFIC template to small-cell disease. It is a single pivotal trial, and whether real-world consolidation series reproduce it is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
730 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Durvalumab | 264 | 55.9 months | 0.73 (0.57 to 0.93) | 0.0104 | link |
| Placebo | 266 | 33.4 months | ||||
| Progression-free survivalprimary | Durvalumab | - | 16.6 months | 0.76 (0.61 to 0.95) | - | link |
| Placebo | - | 9.2 months |
Shares Corinne Faivre-Finn, Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy, Limited-stage vs extensive-stage (small-cell lung cancer), Limited-stage small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer, Limited-stage small-cell lung cancer, Small-cell lung cancer, Lung cancer (all types).
Shares Limited-stage vs extensive-stage (small-cell lung cancer), Limited-stage small-cell lung cancer, Durvalumab, Small-cell lung cancer.
Shares Prophylactic cranial irradiation vs MRI surveillance, ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer, Durvalumab, AstraZeneca.
Shares Prophylactic cranial irradiation vs MRI surveillance, Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy, Limited-stage vs extensive-stage (small-cell lung cancer), Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer, Lung cancer (all types), IMRT / IGRT (modern external beam).